Cargando…
Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial
BACKGROUND: High-density lipoprotein (HDL) levels are inversely associated with cardiovascular risk. Cholesteryl ester transfer protein inhibition with evacetrapib results in a marked increase in HDL and reduction in low-density lipoprotein (LDL) levels. We evaluated the impact of treatment with eva...
Autores principales: | Menon, Venu, Kumar, Anirudh, Patel, Divyang R, St John, Julie, Riesmeyer, Jeffrey, Weerakkody, Govinda, Ruotolo, Giacomo, Wolski, Kathy E, McErlean, Ellen, Cremer, Paul C, Nicholls, Stephen J, Lincoff, A Michael, Nissen, Steven E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073792/ https://www.ncbi.nlm.nih.gov/pubmed/32179516 http://dx.doi.org/10.1136/bmjdrc-2019-000943 |
Ejemplares similares
-
Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High‐Risk Vascular Disease Treated With Statin Therapy
por: Menon, Venu, et al.
Publicado: (2019) -
Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High‐Risk Vascular Disease: Insights From the ACCELERATE Trial
por: Kumar, Anirudh, et al.
Publicado: (2019) -
CETP inhibitor evacetrapib enters mouse brain tissue
por: Phénix, Jasmine, et al.
Publicado: (2023) -
CYP‐mediated drug–drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome
por: Cannady, Ellen A., et al.
Publicado: (2015) -
The Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Evacetrapib Administered as Monotherapy or in Combination With Statins
por: Friedrich, S, et al.
Publicado: (2014)